Is Milestone Pharmaceuticals Inc. (MIST) a Buy, Sell, or Hold?
NASDAQ : MIST
Milestone Pharmaceuticals Inc.
$1.145 USD
-$0.12 (-9.84%)
- Volume
- 5.3M
- Average Volume
- 1.63M
- Market Capitalization
- $142.55M
- P/E Ratio
- -1.66
- Dividend Yield
- 0.00%
- Price Target
- $6.00
- Year High
- $3.06
- Year Low
- $1.00
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $8.13
Company Overview
NASDAQ
Joseph G. Oliveto
Biotechnology
Healthcare
MIST
38
CA
USD
Liquidity Metrics
7.79
8.13
7.92
7.65
0.00
Sales & Valuation
$1.55M
60.84
8.72
-3.69
-0.28
Profitability
-$0.75
-$63.06M
-3585.62%
-3593.38%
-288.36%
-46.26%
P/E Metrics
-1.66
-0.08
-0.08
Analyst Price Target & Rating
$6.00
$6.00
$6.00
1/5
7 Analysts
-80.92%
Financial Health Scores
-2.68
4/9
$171.31M
$193.73M
$157.68M
-$61.51M
Key Metrics (TTM)
$224.12M
125.63
-3.65
9.18
-339.38%
-37.64%
-41.32%
-32.40%
-30471 days
Company Executives
| Name | Title |
|---|---|
| Philippe Douville | Founder, Strategic Advisor & Member of Scientific Advisory Board |
| Joseph G. Oliveto | Chief Executive Officer, President & Director |
| David Bharucha FACC | Chief Medical Officer |
| Guy Rousseau | SVP of Regulatory Affairs and Quality Management |
| Philip T. Sager FACC FAHA FHRS | Chief Medical Advisor & Member of the Scientific Advisory Board |
| Jeff Moore | Vice President of Sales |
| Jeff Nelson | Chief Operating Officer |
| Roshan Girglani | Vice President of Marketing |
| David Sandoval | General Counsel & Chief Compliance Officer |
| Amit Hasija | Chief Financial Officer & Executive Vice President of Corporate Development |
Poll Results
No votes yet today — be the first to share your view!
About Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Stock
Milestone Pharmaceuticals Inc. is a biopharmaceutical company based in Montréal, Canada, specializing in the creation and commercialization of cardiovascular therapeutics. Their flagship product, etripamil, an innovative channel blocker, is currently in advanced clinical development. It is undergoing Phase III trials for the treatment of paroxysmal supraventricular tachycardia (PSVT) in the United States and Canada, while also progressing through Phase II trials for atrial fibrillation and rapid ventricular rate. Furthermore, Milestone Pharmaceuticals has forged a licensing and collaboration alliance with Ji Xing Pharmaceuticals to advance and distribute etripamil for both preventative and therapeutic applications in humans. The company was founded in 2003. ...
Milestone Pharmaceuticals Q2 Earnings Call Highlights
2026-08-12 11:05:30
Milestone Pharmaceuticals NASDAQ: MIST reported early commercial traction for CARDAMYST following its mid-February launch, while advancing a pivotal Phase III study of etripamil in atrial fibrillation with rapid ventricular rate, or AFib-RVR.
Milestone Pharmaceuticals (MIST) Reports Q2 Loss, Lags Revenue Estimates
2026-08-12 09:26:03
Milestone Pharmaceuticals (MIST) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to a loss of $0.2 per share a year ago.
2026-08-12 07:08:00
Over 50% of commercially insured lives in the U.S., representing a recent and significant increase, now have coverage for CARDAMYST® (etripamil) nasal spray
Milestone Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 12, 2026
2026-08-04 16:01:00
MONTREAL and CHARLOTTE, N.C., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that it will report financial results for the second quarter ended June 30, 2026, on Wednesday, August 12, and provide a business update before the market open.
2026-07-29 10:35:23
Milestone Pharmaceuticals (MIST) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-07-02 21:30:39
MONTREAL and CHARLOTTE, N. C. , July 02, 2026 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) (the "Company" or "Milestone"), today announced that the Company granted equity awards, in the form of a total of 288,000 options (the "Options") to purchase the Company's common shares, pursuant to the Company's 2021 Inducement Plan (the "Plan"), previously approved by the Company's Compensation Committee and the Board of Directors, as a material inducement to the hiring of six new employees.
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-07-02 21:30:00
MONTREAL and CHARLOTTE, N.C., July 02, 2026 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) (the “Company” or “Milestone”), today announced that the Company granted equity awards, in the form of a total of 288,000 options (the “Options”) to purchase the Company's common shares, pursuant to the Company's 2021 Inducement Plan (the “Plan”), previously approved by the Company's Compensation Committee and the Board of Directors, as a material inducement to the hiring of six new employees.
Alpha Cognition Announces Election of Dr. Robert Wills as Chairman of the Board
2026-06-23 09:00:00
Alpha Cognition Inc. (Nasdaq: ACOG) (âAlpha Cognitionâ, or the âCompanyâ), a biopharmaceutical company focused on developing novel therapies for debili
Frequently Asked Questions
-
What is the current Milestone Pharmaceuticals Inc. (MIST) stock price?
-
Milestone Pharmaceuticals Inc.(NASDAQ:MIST) stock price is $1.145 in the last trading session. During the trading session, MIST stock reached the peak price of $3.06 while $1 was the lowest point it dropped to. The percentage change in MIST stock occurred in the recent session was --9.84% while the dollar amount for the price change in MIST stock was -$0.12.
-
MIST's industry and sector of operation?
-
The NASDAQ listed MIST is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of MIST?
-
Philippe Douville | Founder, Strategic Advisor & Member of Scientific Advisory Board
Joseph G. Oliveto | Chief Executive Officer, President & Director
David Bharucha FACC | Chief Medical Officer
Guy Rousseau | SVP of Regulatory Affairs and Quality Management
Philip T. Sager FACC FAHA FHRS | Chief Medical Advisor & Member of the Scientific Advisory Board -
How many employees does MIST have?
-
Number of MIST employees currently stands at 38. MIST operates from 1111 Dr. Frederik-Philips Boulevard, Montreal, QC H4M 2X6, CA.
-
Link for MIST official website?
-
Official Website of MIST is: https://www.milestonepharma.com
-
How do I contact MIST?
-
MIST could be contacted at phone #15143360444 and can also be accessed through its website. MIST operates from 1111 Dr. Frederik-Philips Boulevard, Montreal, QC H4M 2X6, CA.
-
How many shares of MIST are traded daily?
-
The average number of MIST shares traded daily for last 3 months was 1.63M.
-
What is the market cap of MIST currently?
-
The market value of MIST currently stands at $142.55M with its latest stock price at $1.145